Background Infections are common complications of neonatal long lines. Heparin has been shown to prolong the effective duration of neonatal long lines and to reduce the ability of bacteria to adhere to foreign surfaces, but the effect of heparin on rates of infection is uncertain.
Objective The goal of this study was to evaluate the effect of heparin on the frequency of episodes of catheter-related sepsis (CRS) in infants receiving total parenteral nutrition (TPN) through a neonatal long line.
Design/Methods This randomised, controlled, double blind, single-centre clinical trial compared heparin at 0.5 IU/ml with no heparin in TPN infused through a neonatal long line, with episodes of CRS as the primary outcome.
Results 210 infants were enrolled (TPN with heparin n=102, TPN without heparin n=108). There was a statistically significant reduction in all episodes of culture-positive CRS in those infants with heparin added to the TPN compared with those without heparin (p=0.04; RR 0.57, 95% CI 0.32 to 0.98; number needed to treat 9, 95% CI 4.6 to 212.4).
Conclusions The addition of heparin at 0.5 IU/ml to TPN infused through a neonatal long line reduces the incidence of culture-positive CRS.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Funding This study was supported by grants from the New Zealand Grants Advisory Subcommittee of the Royal Australasian College of Physicians and the Baxter Clinical Nutrition Grant 2004.
Competing interests None.
Patient consent Obtained from parents.
Ethics approval This study was conducted with the approval of the Wellington Ethics Committee, Ministry of Health, PO Box 5013, approval number: WGT/03/08/079, Wellington.
Provenance and peer review Not commissioned; externally peer reviewed.
This trial was registered on 4 October 2005 (trial start date 5 March 2004) with the Australian New Zealand Clinical Trials Registry (ACTRN12605000579695).